Amgen, Moderna, the Allen Institute, and Thermo Fisher received OpenAI's GPT-Rosalind vertical reasoning model as a research preview for drug discovery and genomics work.
Novo Nordisk partnered with OpenAI to overhaul drug development, with pilots starting immediately in R&D, manufacturing, and commercial and full integration planned by year-end.
Every entry names the organisation and links its source. Outcome figures are quoted as reported, never estimated. Vendor announcements without a named customer are excluded. Halted and reversed deployments are kept on purpose.
Nous utilisons des cookies essentiels au fonctionnement du site (connexion, sécurité des formulaires). Avec votre accord, nous utilisons aussi des cookies analytiques pour comprendre comment vous utilisez le site.
Politique de confidentialité